Press Releases
2008
June 26, 2008:
iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results
June 9, 2008:
iCo Therapeutics Closes $1,140,450 Financing
June 2, 2008:
iCo Therapeutics Announces $1,140,450 Financing
May 30, 2008:
iCo Therapeutics First Quarter Financial Results
May 7, 2008:
iCo Therapeutics Acquires Worldwide Rights to iCo-009 (Oral Amphotericin B)
May 5, 2008:
iCo Therapeutics to Present at BioFinance 2008
April 28, 2008:
iCo Therapeutics Year-End 2007 Financial Results
April 25, 2008:
iCo Therapeutics iCo-007 Diabetic Macular Edema Poster Presentation at ARVO
April 21, 2008:
iCo Therapeutics Announces iCo-009 (Oral Amphotericin B) FDA Meeting
March 17, 2008:
iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading Drug Delivery Journal
March 10, 2008:
iCo Therapeutics Provides iCo-008 Phase II Clinical Update
February 27, 2008:
iCo Therapeutics Announces CMO Invited to Present at International Ocular Conference
January 21, 2008:
iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Update
2007
December 31, 2007:
iCo Therapeutics Inc. and Beanstalk Capital Ltd. Announce Completion of Arrangement
October 31, 2007:
Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
October 16, 2007:
Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc.
October 9, 2007:
Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007
January 22, 2007:
iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema
iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema
January 10, 2007:
iCo Therapeutics announces licensing deal
iCo Therapeutics has announced a licensing deal that gives it worldwide rights for the development and commercialization of CAT-213, a treatment for allergic disorders.
January 8, 2007:
Cambridge Antibody Tech. licenses monoclonal antibody for treatment of allergy disorders to iCo
Cambridge Antibody Technology licenses monoclonal antibody (CAT-213) for treatment of allergy disorders to iCo Therapeutics
View Press Releases Archive >